Methods and products for genetic engineering
Virus-derived particles deliver CRISPR-Cas9 components for efficient and stable genome editing in diverse cell types, addressing limitations of current delivery methods and enhancing large-scale genetic modification capabilities.
JP2026143710APending Publication Date: 2026-09-08INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +3
0 Cites 0 Cited by
Patent Information
- Application Number
- JP2026097560
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2015-10-20
- Filing Date
- 2026-06-11
- Publication Date
- 2026-09-08
AI Technical Summary
Technical Problem
Current CRISPR/Cas9 delivery methods are limited to specific cell types and can be toxic, particularly in primary cells, and are not efficient for large-scale, high-throughput genetic modifications.
Method used
Virus-derived particles, such as lentivirus-derived vector particles, are used to deliver CRISPR-Cas9 components, including Cas proteins and guide RNAs, to target nucleic acids in eukaryotic cells, enabling stable and efficient genome editing.
Benefits of technology
The method allows for efficient and stable genome editing in various cell types, including primary cells, with reduced toxicity and improved efficiency for large-scale applications.
✦ Generated by Eureka AI based on patent content.
Abstract
This provides improved tools and methods for gene editing using CRISPR / Cas technology. [Solution] The present invention provides virus-derived particles containing one or more Cas proteins, as well as kits and methods for using them to alter target nucleic acids.
Need to check novelty before this filing date? Find Prior Art